Insmed Incorporated (NASDAQ:INSM) Receives $94.00 Average PT from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned a consensus recommendation of “Buy” from the sixteen research firms that are covering the firm, Marketbeat reports. Sixteen investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $94.00.

Several analysts have recently weighed in on the company. UBS Group boosted their target price on Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company’s stock, valued at $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 33,055 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50. Following the transaction, the insider now directly owns 138,053 shares of the company’s stock, valued at approximately $11,168,487.70. This trade represents a 19.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 471,797 shares of company stock valued at $37,621,239 in the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Insmed

A number of large investors have recently bought and sold shares of the stock. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after acquiring an additional 2,463,261 shares during the last quarter. Norges Bank acquired a new stake in shares of Insmed during the 4th quarter worth about $126,606,000. Vanguard Group Inc. grew its holdings in shares of Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Brown Advisory Inc. acquired a new position in shares of Insmed in the fourth quarter valued at approximately $45,773,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Insmed by 59.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company’s stock valued at $113,748,000 after buying an additional 615,000 shares during the period.

Insmed Stock Performance

Shares of INSM opened at $70.80 on Thursday. The company has a market capitalization of $12.87 billion, a price-to-earnings ratio of -12.67 and a beta of 1.07. Insmed has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a 50 day moving average price of $74.82 and a 200 day moving average price of $73.56.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Research analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.